ganaxolone

Shares of the actively traded micro-cap biotech Marinus Pharmaceuticals Inc (NASDAQ: MRNS) opened notably higher Thursday morning following a positive clinical readout from the company. What Hapened The shares, which suffered a setback in late July after a failed midstage trial of...

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) is a developer of ganaxolone, a therapy intended to treat patients with a rare genetic disorder, and initial data is "looking good," according to Ladenburg Thalmann. The Analyst Analyst Michael Higgins initiated coverage of Marinus...

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) closed up 39.6 percent Thursday and continued another 3.9 percent pre-market Friday — but not on its own merits. The stock moved mostly on sympathy for SAGE Therapeutics Inc (NASDAQ: SAGE), a biotech peer that released positive clinical data on its...

Oppenheimer has downgraded Marinus Pharmaceuticals Inc (NASDAQ: MRNS) to Perform after the company's first Phase 3 epilepsy study for adult focal onset seizures failed to meet its primary endpoint. Even though company indicated there were certain sub-demographics of better responders in the greater...